KIMMTRAK® tebentafusp 是一种新型双特异性T细胞受体 (TCR) 药物,靶向gp100×CD3。 药物由Immunocore公司开发,2022年获FDA批准上市,用于治疗转移性葡萄膜黑色素瘤。 Tebentafusp国内尚未注册申报,一些文献中称为替本福司(音译无出处)。 1、作用机制 gp100是一种抗原分子,最早在胚胎早期出现。它被认为是黑色素...
对gp100具有特异性的TCR-抗CD3 scFv融合蛋白的定量用药方案本发明涉及癌症的治疗,特别涉及gp100阳性癌症的治疗.特别地,本发明涉及一种T细胞重定向双特异性治疗剂的用量方案,所述双特异性治疗剂包含与YLEPGPVTAHLAA2复合物结合的靶向部分,所述靶向部分与结合CD3的T细胞重定向部分融合.克里斯蒂娜·科格林...
在淘宝,您不仅能发现原装正品MMBD1204[DIODE ARRAY GP 100V 200MA SOT23]的丰富产品线和促销详情,还能参考其他购买者的真实评价,这些都将助您做出明智的购买决定。想要探索更多关于原装正品MMBD1204[DIODE ARRAY GP 100V 200MA SOT23]的信息,请来淘宝深入了解吧!
The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell ...
The present disclosure relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HcLA-A2 complex fused to a CD3 binding T cell ...
The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell ...
This disclosure relates to the treatment of cancer, particularly gp100 positive cancer. Specifically, the present disclosure relates to a dosage regimen for a double specific therapeutic agent that redirects T cells, comprising a targeting portion that couples to the ilppgvta-hla-a2 complex, which ...
The present disclosure relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HcLA-A2 complex fused to a CD3 binding T cell ...
The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell ...
The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell ...